Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.23%AUDUSD-1.17%GBPCHF+1.02%USDCHF+0.94%GBPNZD+0.79%GBPCAD+0.79%NZDUSD-0.75%USDCAD+0.73%AUDJPY-0.69%EURGBP-0.65%USDTHB+0.64%EURAUD+0.60%EURUSD-0.60%GBPJPY+0.57%USDJPY+0.51%AUDCAD-0.47%AUDNZD-0.43%GBPTRY+0.41%CHFJPY-0.40%PLNJPY+0.39%EURCHF+0.34%GBPHKD+0.32%SGDJPY+0.32%USDTRY+0.29%NOKJPY+0.29%GBPMXN-0.28%AUDCHF-0.26%NZDJPY-0.22%CADCHF+0.22%CADJPY-0.21%NZDCHF+0.20%USDZAR+0.20%USDSEK+0.17%EURNZD+0.16%USDILS+0.16%USDMXN+0.14%USDCNH-0.14%USDNOK+0.13%EURCAD+0.13%EURZAR+0.13%GBPZAR+0.11%NZDSGD-0.11%EURSEK+0.11%CHFSEK+0.10%USDSGD+0.10%AUDNOK+0.10%EURJPY-0.09%NZDMXN-0.09%EURNOK+0.09%CHFNOK+0.08%EURHKD-0.07%GBPUSD+0.06%AUDSGD+0.06%USDDKK+0.05%EURSGD+0.04%USDCOP-0.04%USDPLN+0.04%CHFSGD+0.04%USDHKD+0.03%GBPSGD+0.02%EURPLN-0.02%NZDCAD-0.01%AUDDKK+0.01%EURCNH0.00%EURDKK0.00%EURCZK0.00%XAGUSD+0.70%GAGUSD+0.70%HG1-0.64%USOIL-0.49%UKOIL-0.33%S1-0.27%XPTUSD-0.25%COTTON-0.21%XNGUSD-0.08%GAUUSD-0.06%XAUUSD-0.06%C1+0.03%BTCUSD-0.19%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.07%ZECUSDT-0.02%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.57%XLMUSD+2.18%BCHUSDT-0.61%UNIUSD-0.74%LTCUSD+0.07%SUIUSD+1.70%HBARUSDT+1.75%TONUSD+15.77%TAOUSDT+0.27%AAVEUSD-2.45%DOTUSDT+2.87%ICPUSDT-1.58%ONDOUSDT+0.21%WLDUSDT+10.30%ARBUSDT-0.33%JUPUSDT-1.11%ATOMUSDT+1.34%INJUSDT-3.04%STXUSDT+18.01%FETUSDT+3.26%SEIUSDT+0.33%PYTHUSDT-3.04%TIAUSDT-0.07%IMXUSDT+0.97%GRTUSDT-0.44%OPUSDT-0.24%WIFUSDT+3.87%IOTAUSDT+4.03%POLUSDT-4.75%AXSUSDT+0.76%FARTCOINUSDT-0.30%EOSUSDT+4.07%DYDXUSDT+3.32%GALAUSDT+3.85%ORDIUSDT+1.22%NOTUSDT+1.55%RONINUSDT+0.06%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.23%AUDUSD-1.17%GBPCHF+1.02%USDCHF+0.94%GBPNZD+0.79%GBPCAD+0.79%NZDUSD-0.75%USDCAD+0.73%AUDJPY-0.69%EURGBP-0.65%USDTHB+0.64%EURAUD+0.60%EURUSD-0.60%GBPJPY+0.57%USDJPY+0.51%AUDCAD-0.47%AUDNZD-0.43%GBPTRY+0.41%CHFJPY-0.40%PLNJPY+0.39%EURCHF+0.34%GBPHKD+0.32%SGDJPY+0.32%USDTRY+0.29%NOKJPY+0.29%GBPMXN-0.28%AUDCHF-0.26%NZDJPY-0.22%CADCHF+0.22%CADJPY-0.21%NZDCHF+0.20%USDZAR+0.20%USDSEK+0.17%EURNZD+0.16%USDILS+0.16%USDMXN+0.14%USDCNH-0.14%USDNOK+0.13%EURCAD+0.13%EURZAR+0.13%GBPZAR+0.11%NZDSGD-0.11%EURSEK+0.11%CHFSEK+0.10%USDSGD+0.10%AUDNOK+0.10%EURJPY-0.09%NZDMXN-0.09%EURNOK+0.09%CHFNOK+0.08%EURHKD-0.07%GBPUSD+0.06%AUDSGD+0.06%USDDKK+0.05%EURSGD+0.04%USDCOP-0.04%USDPLN+0.04%CHFSGD+0.04%USDHKD+0.03%GBPSGD+0.02%EURPLN-0.02%NZDCAD-0.01%AUDDKK+0.01%EURCNH0.00%EURDKK0.00%EURCZK0.00%XAGUSD+0.70%GAGUSD+0.70%HG1-0.64%USOIL-0.49%UKOIL-0.33%S1-0.27%XPTUSD-0.25%COTTON-0.21%XNGUSD-0.08%GAUUSD-0.06%XAUUSD-0.06%C1+0.03%BTCUSD-0.19%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.07%ZECUSDT-0.02%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.57%XLMUSD+2.18%BCHUSDT-0.61%UNIUSD-0.74%LTCUSD+0.07%SUIUSD+1.70%HBARUSDT+1.75%TONUSD+15.77%TAOUSDT+0.27%AAVEUSD-2.45%DOTUSDT+2.87%ICPUSDT-1.58%ONDOUSDT+0.21%WLDUSDT+10.30%ARBUSDT-0.33%JUPUSDT-1.11%ATOMUSDT+1.34%INJUSDT-3.04%STXUSDT+18.01%FETUSDT+3.26%SEIUSDT+0.33%PYTHUSDT-3.04%TIAUSDT-0.07%IMXUSDT+0.97%GRTUSDT-0.44%OPUSDT-0.24%WIFUSDT+3.87%IOTAUSDT+4.03%POLUSDT-4.75%AXSUSDT+0.76%FARTCOINUSDT-0.30%EOSUSDT+4.07%DYDXUSDT+3.32%GALAUSDT+3.85%ORDIUSDT+1.22%NOTUSDT+1.55%RONINUSDT+0.06%
KT

Kymera Therapeutics, Inc. (KYMR)

NASDAQ • Healthcare

$111.79
+$1.28 (+1.2%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$111.18
Day Range$108.03 - $115.69
Avg. Volume (3M)764.9K
Market Cap$9.1B
52 Week Range
$54.35$130.05
Next EarningsIn 33 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$65M100%
Gross Profitminus cost of goods$65M100%

In plain terms: out of every $100 in revenue, Kymera Therapeutics, Inc. currently loses $94.

Fundamentals & Financials

Revenue (TTM)
$104.9M
Net Income (TTM)
-$299.6M
EPS (TTM)
-$3.25
ROA (TTM)
-18.21%
Current Ratio
9.83

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-23.8%Q1 2026-$0.97
+20.2%Q2 2026-$0.71
+13.0%Q3 2026-$0.62
Next

Nov 3

in 33 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +13.0%

Kymera Therapeutics topped consensus on EPS in the second fiscal quarter of 2026, reported on Aug. 5, with EPS of -$0.62 versus the -$0.71 estimate, about +13%, and improved from -$0.95 a year ago. Gross profit came to about $65.0 million, operating income was negative $75.6 million, and net income was negative $61.2 million, about 20% better than the $76.6 million loss a year earlier. Operating cash flow was negative $54.1 million. For the next period, consensus for the next period calls for EPS of -$1.02 on revenue of $8.0 million.

View full earnings history

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. is a NASDAQ-listed biotechnology company that develops small molecule therapeutics designed to harness the body's protein degradation system to eliminate disease-causing proteins. In healthcare, its work centers on drug discovery and development, and it recorded $39.2 million of revenue in FY2025.

Name
Kymera Therapeutics, Inc.
CEO
Nello Mainolfi
Website
www.kymeratx.com
Industry
Healthcare
Year Founded
2015
Employees
273

Today's Snapshot

AI-generated

KYMR closed 1.2% above yesterday's close, outperforming a weaker sector.

Trading Volume

Above 10d avg 849.3K

1M

vs S&P 500 Today

Outperforming Market

+0.97%

Updated: September 30, 2026 at 20:15 UTC

Technical Indicators

3 Buy1 Neutral4 Sell
KYMR shows mixed signals that support the neutral overall rating: trend strength is weak with ADX around 13.6 while momentum measures are soft, as MACD and short-term momentum read negative and RSI sits below neutral. The price is trading below the short and medium moving averages yet remains above the 200-day band, creating a tension between short-term resistance and longer-term support. Volatility is moderate with ATR near 5.04 and on-balance volume is pointing lower, suggesting limited buying pressure. Technical takeaway: Neutral — short-term weakness offsets longer-term support.
All signals
  • EMA (5 indicators)$93.92 - $115.25
    Sell
  • RSI (14)43.09
    Neutral
  • Stochastic %K (14, 3, 3)16.52
    Buy
  • MACD Level (12, 26)-0.92
    Sell

Peers & Related Assets

CRNXCrinetics Pharmaceuticals, Inc.
$84.950.0%
PRAXPraxis Precision Medicines, Inc.
$291.23+3.6%
IMVTImmunovant, Inc.
$33.78+1.0%
VKTXViking Therapeutics, Inc.
$32.6+2.5%
ACADAcadia Pharmaceuticals Inc.
$20.15-0.3%
ACLXArcellx, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.